International Flavors & Fragrances Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IFF research report →
Range $91 – $108
Price Chart
About the company
International Flavors & Fragrances Inc. (IFF), through its various subsidiaries, operates as a global developer and purveyor of active cosmetic and natural health ingredients. These vital components are incorporated into a wide array of consumer goods distributed across significant markets such as Europe, Africa, the Middle East, Greater Asia, North America, and Latin America.
- CEO
- Jon Erik Fyrwald
- IPO
- 1974
- Employees
- 21,500
- HQ
- New York City, NY, US
AI snapshot
Six angles, distilled from the data.
IFF is in a recovery phase after a long reset, but the stock still sits below its 200-day average and well under the 52-week high. That leaves a mixed regime: improving from the lows, yet not back in a confirmed long-term uptrend.
Street sentiment is constructive but not euphoric, with a Buy consensus and an average target of about $97.75 versus a median of $95. Recent calls have leaned higher on price targets, while several firms kept ratings steady, suggesting cautious optimism rather than a full rerating.
IFF has beaten EPS in 7 of the last 8 quarters, including the last three reports. Next-year EPS estimates point to a sharp step-up to about 3.87 from a 2026 average of 3.31, so shareholders should watch whether margin recovery and execution keep pace with that reset.
The signal is mixed but not bearish. Discretionary buying from director Paul Fribourg was large in June, while recent August sales from the CFO and two other officers add some caution. Most of the other activity is award, vesting, or in-kind related and carries less signal value.
Profitability is still uneven, but operating leverage is present: gross margin is 36.3% and operating margin is 8.13%. Revenue growth is running at 3.9% year over year, while net margin is only 1.68%, so the setup depends on continued margin repair rather than top-line acceleration alone.
IFF’s specialty chemicals franchise spans taste, scent, and biosciences, giving it broader end-market exposure than a pure-play peer. The stock trades at 20.12 times earnings, which is not cheap for a business still working through margin normalization, but it is supported by a 7.2% free-cash-flow yield.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $19.94B
- P/E
- 103.80
- Fwd P/E
- 24.06
- PEG
- 4.52
- P/S
- 2.14
- P/B
- 1.51
- EV/EBITDA
- 21.95
- Div Yield
- 2.03%
- Gross Margin
- 38.87%
- Op Margin
- 7.70%
- Net Margin
- 2.11%
- ROE
- 1.41%
- ROIC
- 2.20%
Latest fiscal year · YoY change
- Revenue
- $10.89B-5.2%
- Gross Profit
- $3.94B-4.5%
- Op Income
- $842.00M
- Net Income
- $-361,000,000-248.6%
- EPS
- $-1.46-253.7%
- OCF Growth
- -20.6%
- FCF Growth
- -57.5%
- 52W High
- $95.27
- 52W Low
- $62.06
- 50D MA
- $86.21
- 200D MA
- $79.39
- Beta
- 0.88
- RSI (14)
- 35
- Avg Volume
- 2.05M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
IFF posted broad-based Q3 growth across all segments, raised the low end of full-year guidance, and said portfolio simplification is improving growth, margins, and cash flow despite Health & Biosciences softness.· November 4, 2026
- Q3 sales were just under $2 billion, up roughly 5% currency neutral, with EBITDA of $403 million, up 6%, and EBITDA margin of 20.8%, up 20 basis points.
- Taste sales rose 6% to $687 million, Scent sales rose 6% to $689 million, and Health & Biosciences rose 1% to $566 million.
- For the first 9 months of 2026, free cash flow was $371 million, up $245 million year over year; cash from operations was $820 million and CapEx was $449 million.
- Management raised the low end of full-year guidance to about $7.5 billion to $7.6 billion of sales and $1.55 billion to $1.6 billion of adjusted operating EBITDA.
- Health & Biosciences remains the key weak spot, with Q4 expected to see softer profitability from higher costs and continued market softness, especially in health supplements.
IFF reported third-quarter revenues of just under $2 billion, up roughly 5% on a comparable currency-neutral basis, with EBITDA of $403 million, up 6%, and EBITDA margin of 20.8%, up 20 basis points. By segment, Taste sales increased 6% to $687 million with EBITDA up 7% to $128 million; Scent sales increased 6% to $689 million with EBITDA up 10% to $139 million; and Health & Biosciences sales increased 1% to $566 million with EBITDA up 2% to $139 million. For the first 9 months of 2026, sales grew 4%, EBITDA rose 7%, adjusted operating EBITDA margin improved by 50 basis points, and free cash flow was $371 million, up $245 million from last year. Management raised the low end of full-year guidance and now expects sales of approximately $7.5 billion to $7.6 billion and adjusted operating EBITDA of $1.55 billion to $1.6 billion. Q4 sales are expected to still grow, around the 3% range plus or minus, but Q4 profitability margin is expected to moderate sequentially because of seasonality, higher costs, and reinvestment, especially in Health & Biosciences.
Erik Fyrwald framed the quarter as evidence that IFF’s portfolio transformation is working, saying the company is becoming more focused, higher growth, and more margin-accretive. He emphasized broad-based execution, stronger innovation, and new wins across Taste and Scent, while acknowledging that Health & Biosciences is being pressured by weak consumer demand for dietary supplements in the U.S. and Europe. His tone was confident but measured: the company sees momentum, but he repeatedly noted macro uncertainty and the need to keep working through pricing, productivity, and reinvestment.
Michael DeVeau highlighted the hard numbers behind the quarter: revenue just under $2 billion, EBITDA of $403 million, and margin of 20.8%, plus year-to-date free cash flow of $371 million and operating cash flow of $820 million. He said CapEx was $449 million, or about 5.4% of sales, and that the company returned $306 million to shareholders through dividends and $584 million through share repurchases in the first 9 months, including completion of a $500 million accelerated share repurchase for about 5.8 million shares. He also noted gross debt of about $6.3 billion, cash and equivalents of $519 million, and net debt to credit-adjusted EBITDA of 2.75x, with debt expected to be repaid using Food Ingredients divestiture proceeds.
Analysts pressed management on Health & Biosciences softness, higher raw material and energy costs, pricing timing, Q4 sales moderation, and the pace of the Food Ingredients separation and stranded-cost reduction. Management said the H&B weakness is mainly a market issue tied to reduced supplement spending, while the cost pressure is broad-based, led by oil derivatives, energy, and logistics rather than raw materials alone. On pricing, DeVeau said the company is actively in pricing discussions now and expects the gap to close through 2027, while on the divestiture he said about two-thirds of roughly $100 million in stranded costs should be eliminated within 12 months of closing, with execution risk mainly around balancing separation work and cost takeout.
The bull case is that IFF is showing sustained broad-based volume growth, with Taste and Scent both growing 6% and Health & Biosciences still positive despite weakness in one submarket. Management believes innovation, new wins, and a sharper portfolio are lifting growth and margins, while free cash flow and shareholder returns are improving materially. The company also pointed to a cleaner, higher-quality business mix after divestitures, which it says should support stronger long-term growth and cash conversion.
The main bear case is that Health & Biosciences is still under pressure, with management explicitly citing soft end markets for dietary supplements and higher costs in Q4. Pricing recovery is lagging costs in the near term, and management said Q4 margin will moderate sequentially because of seasonality, higher logistics/energy costs, and reinvestment. There is also execution risk around the Food Ingredients separation, stranded-cost reduction, and the continued need to manage leverage while the transaction closes.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.7%
- Shares Outstanding
- 250.39M
- Float Shares
- 249.69M
of shares held by institutions
773 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for IFF, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Oct 13, 26 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Jan 15, 26 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Jan 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Nov 18, 25 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Nov 14, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 29, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 5, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 26, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 4, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jul 25, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | May 15, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Sell | Apr 7, 25 | Filing → |
| Gary C. PetersSenate · MI | Sell | May 14, 24 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Dodge & Cox | 35.21M | ▼ 1.80M |
| Vanguard Group Inc | 30.35M | ▼ 778.43K |
| Freemont Capital Pte Ltd | 25.36M | 0 |
| Blackrock, Inc. | 23.04M | ▼ 134.39K |
| Vanguard Capital Management LLC | 16.26M | ▲ 5.54K |
| State Street Corp | 12.69M | ▲ 352.05K |
| Vanguard Portfolio Management LLC | 11.59M | ▼ 18.43K |
| First Eagle Investment Management, LLC | 9.42M | ▲ 10.25K |
| Invesco Ltd. | 9.30M | ▼ 103.56K |
| Geode Capital Management, LLC | 6.86M | ▲ 51.00K |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Americas LLC | 6.11M | ▼ 94.58K |
| First Pacific Advisors, LP | 5.52M | ▲ 69.87K |
Held by 1,588 ETFs
Biggest fund positions in IFF by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 3, 26 | Winder Pte. Ltd. | other | 0 |
| Nov 2, 26 | Khan Mehmood | other | 1,215.259 |
| Nov 2, 26 | Fyrwald J Erik | other | 7,397 |
| Aug 17, 26 | Teles de Mendonca Ana Paula | sell | 5,718 |
| Aug 7, 26 | Birenkrant Marc | sell | 1,000 |
| Aug 6, 26 | DeVeau Michael | sell | 8,825 |
| Jun 1, 26 | FRIBOURG PAUL J | buy | 260,000 |
| Jun 1, 26 | FRIBOURG PAUL J | buy | 13,500 |
| May 4, 26 | Teles de Mendonca Ana Paula | other | 708 |
| May 4, 26 | Teles de Mendonca Ana Paula | other | 708 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IFF coverage
Recent articles, reports, and earnings notes.

International Flavors & Fragrances (IFF): Recovery, but Leverage Lingers
IFF is showing better operating momentum as Taste, Scent, and Health & Biosciences grow, but heavy debt and a still-premium valuation keep the stock at Hold.

International Flavors & Fragrances Inc. (IFF) slips after deep earning
International Flavors & Fragrances Inc. (IFF) beat EPS and revenue estimates, but shares slipped as investors looked past the headline to softer fourth-quarter profit guidance and a revenue outlook still below the Street’s midpoint. Our deep dive breaks down segment growth, margin trends, and what the updated guidance really signals.

International Flavors & Fragrances Inc. (IFF) drops on earnings beats
International Flavors & Fragrances Inc. (IFF) drops 5.9% after reporting earnings beats, as investors react to the latest quarterly results and outlook.
Want a deeper read on IFF?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
IFF to Boost Fragrance and Beauty Innovation With First Forest Lab
zacks.com · Nov 19
IFF Opens Its First Forest Lab in Brazil's Atlantic Forest to Advance Fragrance and Beauty Innovation
businesswire.com · Nov 18
IFF Launches CONCEPT MUSE, an AI-Powered Platform Designed to Accelerate Food and Beverage Product Development
businesswire.com · Nov 12
Why International Flavors (IFF) International Revenue Trends Deserve Your Attention
zacks.com · Nov 9
International Flavors & Fragrances Q3 Earnings Call Highlights
marketbeat.com · Nov 7
International Flavors & Fragrances Inc. (IFF) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
IFF Earnings Beat Estimates in Q3 on Taste & Scent Strength
zacks.com · Nov 4
International Flavors (IFF) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 19, 2026 · Live quote · Not investment advice